Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.55 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CCKBR | P32239 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393529 | 0.83 | PRKCA (0.44) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL804071 | 0.83 | PRKCA (0.53) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL3580766 | 0.83 | PRKCA (0.60) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL3571775 | 0.82 | PRKCA (0.52) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL4822919 | 0.82 | PRKCA (0.51) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL3587467 | 0.81 | PRKCA (0.51) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL14436045 | 0.81 | PRKCA (0.53) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL11948207 | 0.80 | PRKCA (0.51) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL3592700 | 0.80 | PRKCA (0.51) | PRKCAMMP12NR1I2SCN9ACYP3A4 | |
| SCHEMBL12427557 | 0.80 | PRKCA (0.51) | PRKCAMMP12NR1I2SCN9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121707-B1 | ANTIVIRAL INDOLES | ANGELETTI P IST RICHERCHE BIO (IT) | 2012-12-05 | — | — | EP | disclosed |
| US-8101595-B2 | Antiviral indoles | Istituto di Ricerche di Biologia Molecolare P. Angletti SpA (IT) | 2012-01-24 | — | — | US | disclosed |
| US-7989438-B2 | Therapeutic compounds | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-08-02 | — | — | US | disclosed |
| EP-2178886-A1 | MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-04-28 | — | — | EP | disclosed |
| US-20100076046-A1 | Antiviral Indoles | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-03-25 | — | — | US | disclosed |
| US-20090048239-A1 | Therapeutic compounds | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
| WO-2009010785-A1 | MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076046-A1 | Antiviral Indoles | IDO1, ZC3HAV1, IFNAR1 | PRKCA 4625/4885MMP12 2333/4885NR1I2 674/4885 |
| US-20090048239-A1 | Therapeutic compounds | RRP1B, RCE1, CTSZ | PRKCA 4250/4885MMP12 2067/4885NR1I2 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.